title: Managed care's atypical response. New antipsychotics show promise, but are they getting into enough hands?
authors.forename: T
authors.initials: T
authors.lastname: Waldron
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003363:Cost Control; D017281:Cost of Illness; D017723:Drug Utilization Review; D005569:Formularies as Topic; D006801:Humans; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D008484:Medicaid / Q000191:economics / Q000592:standards; D001523:Mental Disorders / Q000188:drug therapy / Q000191:economics; D010349:Patient Compliance; D010359:Patient Readmission / Q000191:economics; D017410:Practice Guidelines as Topic; D014481:United States
chemical_list: D014150:Antipsychotic Agents